{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:48:42Z","timestamp":1792702122888,"version":"4.5.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy and safety of Vedolizumab (VDZ) combined with Five-flavor sophora flavescens enteric-coated capsules (FSEC) for induction therapy in Ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>UC patients treated with FSEC and\/or VDZ were enrolled and divided into combination group (VDZ+FSEC) and single drug group (VDZ). The primary end points were clinical and endoscopic response and remission rates at week 14 and week 52. Secondary end points were the 14-week corticosteroid withdrawal rate, the number of bowel movements, the number of bloody stools, improvement in inflammatory markers, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The clinical response rate (97.4% vs. 79.1%, P\u00a0=\u00a00.011, 95% confidence interval(CI) 4.1%, 32.8%) and endoscopic response rate (74.4% vs. 51.2%, P\u00a0=\u00a00.031, 95%CI 2.2%, 41.4%) at week 14 in the combination group were significantly higher than those in the single-agent group. PP analysis showed that the endoscopic response rate at week 52 in the combination group was significantly better than that in the monotherapy group (85.7% vs. 62.5%, P\u00a0=\u00a00.042, 95%CI 2.0%, 44.4%), but there was no significant difference in ITT analysis. At week 14, the number of bowel movements and hematochezia scores were significantly improved in the combination group and the monotherapy group, and the improvement in the combination group was more significant at early stage and multiple time points. There were no serious adverse reactions in the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FSEC combined with VDZ demonstrated superior clinical response rates and endoscopic response rates, and had greater advantages in early improvement of hematochezia and defecation frequency, compared to VDZ monotherapy, with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1791086","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:50:22Z","timestamp":1776837022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A single-center clinical study on the combination of Five-flavor sophora flavescens enteric-coated capsules and vedolizumab in induction therapy for ulcerative colitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinglang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shengjing Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflammation Bowel Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1142\/s0192415x2550017x","article-title":"A comprehensive review of traditional Chinese medicine in the management of ulcerative colitis","volume":"53","author":"Xu","year":"2025","journal-title":"Am J Chin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9521073","article-title":"Integrating pharmacology and microbial network analysis with experimental validation to reveal the mechanism of composite Sophora colon\u2010soluble capsule against ulcerative colitis","volume":"2020","author":"Ding","year":"2020","journal-title":"Evidence\u2010Based Complementary Altern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603476","article-title":"Efficacy and safety of Sophora flavescens (Kushen) based traditional Chinese medicine in the treatment of ulcerative colitis: clinical evidence and potential mechanisms","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02900-z","article-title":"Constructing a screening model to obtain the functional herbs for the treatment of active ulcerative colitis based on herb-compound-target network and immuno-infiltration analysis","volume":"397","author":"Ou","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12876-022-02347-1","article-title":"Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"22","author":"Peyrin-Biroulet","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/nejmoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-018-0049-2","article-title":"Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro\/SS) diary","volume":"2","author":"Higgins","year":"2018","journal-title":"J patient-reported outcomes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B12","article-title":"Subacute toxicity study of indirubin in dogs","volume":"12","author":"Du","year":"1981","journal-title":"Chin Tradit Herb Drugs"},{"key":"B13","first-page":"59","article-title":"Hepatic injury caused by Compound Qingdai Capsules: 1 case report","volume":"9","author":"Zhang","year":"2002","journal-title":"China J Chin Med Inf"},{"key":"B14","first-page":"1659","article-title":"Liver injury caused by oral Compound Qingdai Pills: a case report","volume":"7","author":"Fang","year":"2004","journal-title":"Chin Gen Pract"},{"key":"B15","first-page":"340","article-title":"Drug-induced hepatitis caused by Compound Qingdai Pills: 1 case report","volume":"7","author":"Li","year":"2003","journal-title":"Anhui Med Pharm J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:50:23Z","timestamp":1776837023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1791086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2026.1791086"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1791086","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1791086"}}